Klin Onkol 1995; 8(6): 161-164.
Summary: The author gives a review of the use of thymostimulin in the treatment of tumor patients. He shows the basic biochemical and biologic characteristics of this drug, the mechanism of action in malignant tumors, the acceptance of the TP-1 Serono preparation, the dosage, and the method of application. He cites literature demonstrating the effectivity of thymostimulin in adjuvancy, which enhances regeneration of cellular immunity after cytotoxic therapeutic therapy, and thereby significantly improves the effect of the combination antitumor treatment. Under its influence, the negative cytotoxic effect of therapy is reduced. Thus, therapy can be better tolerated, allowing drugs to be administered to their full potential, and is accompanied by a reduction in the incidence of secondary infection, shortening the neccessary time of hospitalisation. This approach prolongs life expectancy, improves the quality of life, and in the end lowers the cost of combination therapy.
